Journal: Continence (Amsterdam, Netherlands)
Article Title: Endogenous vasopressin and vasopressin receptor 2 in bladder as anti-diuretic / anti-spasmodic targets for the treatment of multifactorial nocturia
doi: 10.1016/j.cont.2025.102292
Figure Lengend Snippet: Direct effect of fedovapagon on detrusor relaxation and bladder overactivity. A. Schematic for methodology of tethered bladder cystometry in conscious mice. B. Representative bladder pressure traces of awake mice where fedovapagon (100 nM, in saline) was continuously infused into the bladder through the catheter with or without the presence of systemic VR2 antagonist, lixivaptan. C. Examples of bladder pressure traces recorded isovolumetrically (with the urethra closed) while the bladders were filled with soybean oil with or without fedovapagon. Representative bladder pressure traces from the mouse instilled with acrolein before ( D. ) and after ( E. ) IM fedovapagon administration (See for parameters).
Article Snippet: dAVP acetate (Selleck Chemicals LLC, Houston, TX), AVP, fedovapagon and lixivaptan (MedChemExpress LLC, Monmouth Junction, NJ) were dissolved in saline (dAVP acetate) or DMSO to form stock solutions and stored as aliquots at −30 °C.
Techniques: Saline